睿知中国疾病研究地图
候选清单0

即将招募鼻咽癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07540390,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 65 岁;性别:不限

    登记记录的入选字段

  2. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III).

    入选标准第 3 条

  3. Stage III: TanyN3M0 / T4N0-2M0 (9th AJCC/UICC staging system).

    入选标准第 5 条

  4. Participation in another clinical trial of an investigational drug within 3 months prior to treatment.

    排除标准第 4 条

  5. Hemoglobin (HGB) ≥90 g/L, white blood cell count (WBC) ≥4.0×10\^9 /L, platelet count (PLT) ≥100×10\^9/L.

    入选标准第 7 条

    Liver function: ALT and AST <2.5× upper limit of normal (ULN); total bilirubin <2.0×ULN.

    入选标准第 8 条

    Renal function: serum creatinine <1.5×ULN.

    入选标准第 9 条

  6. HIV-positive; HBsAg-positive with detectable HBV DNA copy number (quantitative detection ≥1000 cps/mL); positive hepatitis C antibody (HCV Ab) with detectable HCV RNA.

    排除标准第 10 条

  7. Age 18-65 years, male or non-pregnant female.

    入选标准第 2 条

    Positive pregnancy test in women of childbearing potential, or lactating women.

    排除标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07540390,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary participation and signed informed consent.
  2. Age 18-65 years, male or non-pregnant female.
  3. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III).
  4. Previously untreated patients with no history of other malignancies; initial treatment for nasopharyngeal carcinoma.
  5. Stage III: TanyN3M0 / T4N0-2M0 (9th AJCC/UICC staging system).
  6. ECOG performance status 0-1, with no severe dysfunction of vital organs (heart, lung, liver, kidney, etc.).
  7. Hemoglobin (HGB) ≥90 g/L, white blood cell count (WBC) ≥4.0×10\^9 /L, platelet count (PLT) ≥100×10\^9/L.
  8. Liver function: ALT and AST <2.5× upper limit of normal (ULN); total bilirubin <2.0×ULN.
  9. Renal function: serum creatinine <1.5×ULN.

排除标准:Exclusion Criteria:

  1. Patients with recurrent or distant metastatic nasopharyngeal carcinoma.
  2. Pathologically confirmed keratinizing squamous cell carcinoma (WHO type I).
  3. Receipt of systemic or topical glucocorticoid therapy within 4 weeks prior to enrollment.
  4. Participation in another clinical trial of an investigational drug within 3 months prior to treatment.
  5. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  6. Patients with idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans), radiation pneumonitis that is clinically symptomatic or requires steroid therapy, active pneumonitis, or other moderate-to-severe pulmonary diseases that significantly affect lung function.
  7. Comorbidities requiring long-term immunosuppressive medication or systemic/topical corticosteroids at immunosuppressive doses.
  8. Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibodies targeting T-cell co-stimulatory or checkpoint pathways) with documented disease progression at the time of study entry.
  9. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis). Patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be included; patients requiring bronchodilators for medical management of asthma are excluded.
  10. HIV-positive; HBsAg-positive with detectable HBV DNA copy number (quantitative detection ≥1000 cps/mL); positive hepatitis C antibody (HCV Ab) with detectable HCV RNA.
  11. Receipt of any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine) within 4 weeks prior to enrollment.
  12. Positive pregnancy test in women of childbearing potential, or lactating women.
  13. Inability to comply with scheduled follow-up due to psychological, social, family, or geographical reasons.

引自 ClinicalTrials.gov, NCT07540390, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07540390,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07540390